In a nationwide study of 3,818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not supporting the hypothesis of a clinically relevant involvement of DPP4 in COVID-19 development and progression.

Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths

Dauriz M;
2020-01-01

Abstract

In a nationwide study of 3,818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not supporting the hypothesis of a clinically relevant involvement of DPP4 in COVID-19 development and progression.
2020
COVID-19; diabetes; DPP4 inhibitors; death
File in questo prodotto:
File Dimensione Formato  
PIIS0168822720306975.pdf

Open Access dal 02/01/2020

Tipologia: Documento in Pre-print
Licenza: Accesso ristretto
Dimensione 508.41 kB
Formato Adobe PDF
508.41 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1028209
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact